BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The National Drug Abuse Treatment Clinical Trials Network - Northeast Node - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The National Drug Abuse Treatment Clinical Trials Network - Northeast Node
X-ORIGINAL-URL:https://www.ctnnortheastnode.org
X-WR-CALDESC:Events for The National Drug Abuse Treatment Clinical Trials Network - Northeast Node
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260513T170000
DTEND;TZID=America/New_York:20260513T180000
DTSTAMP:20260506T130741
CREATED:20260504T201144Z
LAST-MODIFIED:20260504T201144Z
UID:3462-1778691600-1778695200@www.ctnnortheastnode.org
SUMMARY:Medetomidine Impacts on Clinical Management and Systems of Care
DESCRIPTION:ORN Spring 2026 Hot Topics in Addiction Medicine\n\nDescription: \nMedetomidine\, a highly potent veterinary alpha-2 adrenergic agonist\, has recently emerged as a significant adulterant within the U.S. illicit opioid supply. This presentation entitled will review the introduction of medetomidine in the U.S. drug supply\, the pharmacology and clinical effects of medetomidine\, and the distinguishing features of medetomidine toxicity and withdrawal. We will outline emerging treatment strategies emphasizing early\, aggressive alpha-2 agonist therapy; nuanced antiemetic approaches; when and how to escalate to IV dexmedetomidine; and approaches to concurrent opioid withdrawal management. Participants will gain insight into diagnostic challenges\, observation and disposition considerations\, and strategies for system-level preparedness. \nLearning Objectives:\n\nDescribe the emergence of medetomidine as an illicit drug adulterant and its impact on overdose toxicity and withdrawal presentations.\nRecognize the clinical features of medetomidine toxicity and differentiate medetomidine withdrawal from withdrawal syndromes.\nApply evidence-informed strategies for early\, aggressive management of medetomidine withdrawal\, including the use of alpha-2 agonists and antiemetic therapies.\nIdentify system-level challenges posed by medetomidine and outline approaches to multidisciplinary coordination.\n\nMichael Lynch\, MD \nREGISTER
URL:https://www.ctnnortheastnode.org/event/medetomidine-impacts-on-clinical-management-and-systems-of-care/
CATEGORIES:Other Related
END:VEVENT
END:VCALENDAR